Current status of co-occurring mood and substance use disorders: A new therapeutic target

American Journal of Psychiatry

Volumn 170, Issue 1, 2013, Pages 23-30

  Pettinati, Helen M ^a   O'Brien, Charles P ^a   Dundon, William D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ANTIDEPRESSANT AGENT; CITICOLINE; DESIPRAMINE; FLUOXETINE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ALCOHOLISM; BIPOLAR DISORDER; CLINICAL FEATURE; COCAINE DEPENDENCE; COMORBIDITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE; SYMPTOM;

EID: 84872055756     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12010112     Document Type: Review

References (50)

1. Hasin DS, Goodwin RD, Stinson FS, Grant BF: Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62:1097-1106
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617-627
3. Nunes EV, Selzer J, Levounis P, Davies CA: Substance Dependence and Co-Occurring Psychiatric Disorders. Kingston, NJ, Civic Research Institute, 2010
4. Nunes EV, Hennessy G, Slezer J: Depression in patients with substance use disorders, in Substance Dependence and Co- Occurring Psychiatric Disorders. Edited by Nunes EV, Selzer J, Levounis P, Davies CA. Kingston, NJ, Civic Research Institute, 2010, pp 1.1-1.36
5. Westermeyer JJ: Addressing co-occurring mood and substance use disorders, in Integrated Treatment for Mood and Sustance Use Disorders. Edited by Westermeyer JJ, Weiss RD, Ziedonis DM. Baltimore, Johns Hopkins University Press, 2003, pp 1-16
6. Weiss RD, Grif fin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, Doreau HR, Hennen JA: A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 2007; 164:100-107
7. Roman PM, Abraham AJ, Knudsen HK: Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav 2011; 36:584-589
8. Schuckit MA: Comorbidity between substance use disorders and psychiatric conditions. Addiction 2006; 101(suppl 1):76-88
9. Greenfield SF: The assessment of mood and substance use disorders. Edited by Westermeyer JJ, Weiss RD, Ziedonis DM. Baltimore, Johns Hopkins University Press, 2003, pp 42-67
10. Benson TG, Bender RE, Muchoswki PM, Weiss RD: Bipolar disorder in patients with substance use disorders, in Substance Dependence and Co-Occurring Psychiatric Disorders. Edited by Nunes EV, Selzer J, Levounis P, Davies CA. Kingston, NJ, Civic Research Institute, 2010, pp 2.1 -2.30
11. van Zaane J, van den Brink W, Draisma S, Smit JH, Nolen WA: The effect of moderate and excessive alcohol use on the course and outcome of patients with bipolar disorders: a prospective cohort study. J Clin Psychiatry 2010; 71:885- 893
12. Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP: A double-blind, placebocontrolled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010; 167:668-675
13. Hasin DS, Stinson FS, Ogburn E, Grant BF: Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64:830 -842
14. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552
15. Meyer RE: Prospects for a rational pharmacotherapy of alcoholism. J Clin Psychiatry 1989; 50:403-412
16. Pettinati HM: Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry 2004; 56: 785-792
17. Kendler KS, Prescott CA, Myers J, Neale MC: The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003; 60:929 -937
18. Gilman SE, Abraham HD: A longitudinal study of the order of onset of alcohol dependence and major depression. Drug Alcohol Depend 2001; 63:277-286
19. Boschloo L, van den Brink W, Penninx BW, Wall MM, Hasin DS: Alcohol-use disorder severity predicts first-incidence of depressive disorders. Psychol Med 2012; 42:695 -703
20. Conway KP, Compton W, Stinson FS, Grant BF: Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2006; 67:247-257
21. Mueller TI, Lavori PW, Keller MB, Swartz A, Warshaw M, Hasin D, Coryell W, Endicott J, Rice J, Akiskal H: Prognostic effect of the variable course of alcoholism on the 10-year course of depression. Am J Psychiatry 1994; 151:701-706
22. Greenfield SF, Weiss RD, Muenz LR, Vagge LM, Kelly JF, Bello LR, Michael J: The effect of depression on return to drinking: a prospective study. Arch Gen Psychiatry 1998; 55:259-265
23. Hasin D, Liu X, Nunes E, McCloud S, Samet S, Endicott J: Effects of major depression on remission and relapse of substance dependence. Arch Gen Psychiatry 2002; 59:375-380
24. Aharonovich E, Liu X, Nunes E, Hasin DS: Suicide attempts in substance abusers: effects of major depression in relation to substance use disorders. Am J Psychiatry 2002; 159:1600-1602
25. Kranzler HR, Del Boca FK, Rounsaville BJ: Comorbid psychiatric diagnosis predicts three-year outcomes in alcoholics: a posttreatment natural history study. J Stud Alcohol 1996; 57: 619-626
26. Fortney JC, Booth BM, Curran GM: Do patients with alcohol dependence use more services? A comparative analysis with other chronic disorders. Alcohol Clin Exp Res 1999; 23:127-133
27. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB: A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence strati fied on the presence or absence of major depression. JAMA 1996; 275:761-767
28. Brady KT, Sonne SC, Malcolm RJ, Randall CL, Dansky BS, Simpson K, Roberts JS, Brondino M: Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol 2002; 10:276-285
29. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME: Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62:37-45
30. Brown ES, Garza M, Carmody TJ: A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry 2008; 69:701- 705
31. Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S: A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res 2010; 34:1822 -1831
32. Brown ES, Carmody TJ, Schmitz JM, Caetano R, Adinoff B, Swann AC, John Rush A: A randomized, double-blind, placebocontrolled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res 2009; 33:1863 -1869
33. Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT: A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord 2012; 14:54 -63
34. Brown ES, Gorman AR, Hynan LS: A randomized, placebocontrolled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007; 27:498-502
35. Jaffee WB, Griffin ML, Gallop R, Meade CS, Graff F, Bender RE, Weiss RD: Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders. J Clin Psychiatry 2009; 70:171-176
36. Fleck DE, Arndt S, DelBello MP, Strakowski SM: Concurrent tracking of alcohol use and bipolar disorder symptoms. Bipolar Disord 2006; 8:338-344
37. Ostacher MJ, Perlis RH, Nierenberg AA, Calabrese J, Stange JP, Salloum I, Weiss RD, Sachs GS; STEP-BD Investigators: Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2010; 167:289 -297
38. Fossey MD, Otto MW, Yates WR, Wisniewski SR, Gyulai L, Allen MH, Miklowitz DJ, Coon KA, Ostacher MJ, Neel JL, Thase ME, Sachs GS, Weiss RD; Step-BD Investigators: Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants. Am J Addict 2006; 15:138-143
39. Nunes EV, Levin FR: Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004; 291:1887-1896
40. Davis LL, Wisniewski SR, Howland RH, Trivedi MH, Husain MM, Fava M, McGrath PJ, Balasubramani GK, Warden D, Rush AJ: Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend 2010; 107:161-170
41. Carpenter KM, Brooks AC, Vosburg SK, Nunes EV: The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend 2004; 74:123-134
42. Ciraulo DA, Knapp C, Rotrosen J, Sarid-Segal O, Ciraulo AM, LoCastro J, Greenblatt DJ, Leiderman D: Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction 2005; 100(suppl 1):23-31
43. Mason BJ: Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res 1996; 20(suppl 7):10A-16A
44. Pettinati HM: The use of selective serotonin uptake inhibitors (SSRIs) in treating alcohol subtypes. J Clin Psychiatry 2001; 62 (suppl 20):26 -31
45. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, Black A: Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54:700-705
46. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, Hasin D, Keller M: Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006; 26:13-20
47. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF: The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res 2012; 36:385- 394
48. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP: A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28:1546-1552
49. Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias AJ, Pettinati H, Oncken C: A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol 2011; 31:22-30
50. Babor TF, Dolinsky ZS, Meyer RE, Hesselbrock M, Hofmann M, Tennen H: Types of alcoholics: concurrent and predictive validity of some common classification schemes. Br J Addict 1992; 87:1415-1431